Pierre Rivet - Publications

Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted clinical trials: a retrospective cohort analysis.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 02, 2025

Immunohistochemistry, Molecular Biology, and Clinical Scoring for the Detection of Muir-Torre Syndrome in Cutaneous Sebaceous Tumors: Which Strategy?

Journal: Dermatology (Basel, Switzerland)

Published: December 23, 2022

MEOX2 Transcription Factor Is Involved in Survival and Adhesion of Glioma Stem-like Cells.

Journal: Cancers

Published: October 18, 2021

Cell Cycle Changes after Glioblastoma Stem Cell Irradiation: The Major Role of RAD51.

Journal: International journal of molecular sciences

Published: August 17, 2018

Prognostic significance of MEOX2 in gliomas.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: July 13, 2018

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Journal: Cancer biomarkers : section A of Disease markers

Published: August 12, 2017

Crizotinib targets in glioblastoma stem cells.

Journal: Cancer medicine

Published: April 25, 2017

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.

Journal: Oncotarget

Published: May 18, 2016

A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells.

Journal: BMC cancer

Published: August 13, 2015

Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.

Journal: Molecular cancer therapeutics

Published: July 24, 2014

Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 02, 2014

O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.

Journal: International journal of molecular sciences

Published: April 07, 2012